Skip to content
2000
Volume 22, Issue 1
  • ISSN: 1573-4048
  • E-ISSN: 1875-6581

Abstract

Menopausal Hormone Therapy (MHT) is widely used to manage the symptoms of menopause and address long-term health risks associated with estrogen deficiency. This comprehensive review provides an in-depth analysis of MHT, encompassing its benefits, risks, and evolving clinical guidelines. The review begins by outlining the physiological changes occurring during menopause, such as decreased estrogen levels, and their impact on various bodily systems. MHT is discussed in the context of alleviating common menopausal symptoms, including vasomotor symptoms (hot flashes and night sweats), vaginal dryness, and mood disturbances. The review explores the different forms of MHT, including estrogen-only therapy and combined estrogen-progestogen therapy, and examines their indications based on patient characteristics, such as age, time since menopause, and individual risk factors. It critically evaluates the effects of MHT on bone health, cardiovascular disease, and cancer risk, drawing from evidence provided by major clinical trials like the Women’s Health Initiative and observational studies. Recent developments, such as the use of bioidentical hormones and tailored MHT regimens, are also highlighted. Current controversies, such as the balance of benefits risks and the impact of MHT on various health outcomes, are discussed in the context of updated clinical guidelines from leading health organizations. The review emphasizes the importance of personalized treatment strategies to optimize outcomes and minimize risks. By synthesizing current evidence and guidelines, this review aims to offer healthcare providers and patients a thorough understanding of MHT, facilitating informed decision-making and personalized care strategies for menopausal women.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cwhr/10.2174/0115734048352354250406163635
2025-04-23
2026-01-11

  • From This Site

    /content/journals/cwhr/10.2174/0115734048352354250406163635
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. AshinaS. MitsikostasD.D. LeeM.J. YamaniN. WangS.J. MessinaR. AshinaH. BuseD.C. Pozo-RosichP. JensenR.H. DienerH.C. LiptonR.B. Tension-type headache.Nat. Rev. Dis. Primers2021712410.1038/s41572‑021‑00257‑233767185
     [Google Scholar]
  2. BaberR.J. PanayN. FentonA. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy.Climacteric201619210915010.3109/13697137.2015.112916626872610
     [Google Scholar]
  3. BansalR. AggarwalN. Menopausal hot flashes: A concise review.J Midlife Health201910161310.4103/jmh.JMH_7_1931001050
     [Google Scholar]
  4. BeerA.M. OsmersR. SchnitkerJ. BaiW. MueckA.O. MedenH. Efficacy of black cohosh (Cimicifuga racemosa) medicines for treatment of menopausal symptoms – comments on major statements of the Cochrane Collaboration report 2012 “black cohosh (Cimicifuga spp.) for menopausal symptoms (review)”.Gynecol. Endocrinol.201329121022102510.3109/09513590.2013.83183623992293
     [Google Scholar]
  5. BigliaN. BounosV.E. De SetaF. NappiR.E. PaolettiA.M. Non-hormonal strategies for managing menopausal symptoms in cancer survivors: An update.Ecancermedicalscience20191390910.3332/ecancer.2019.90931123492
     [Google Scholar]
  6. BruceD. RobinsonJ. McWilliamsS. ReddyM. FentimanI. RymerJ. Long-term effects of tibolone on mammographic density.Fertil. Steril.20048251343134710.1016/j.fertnstert.2004.03.06315533357
     [Google Scholar]
  7. BurgerH.G. HaleG.E. DennersteinL. RobertsonD.M. Cycle and hormone changes during perimenopause.Menopause200815460361210.1097/gme.0b013e318174ea4d18574431
     [Google Scholar]
  8. BurkardT. MoserM. RauchM. JickS.S. MeierC.R. Utilization pattern of hormone therapy in UK general practice between 1996 and 2015: A descriptive study.Menopause201926774174910.1097/GME.000000000000130030889086
     [Google Scholar]
  9. CarusoD. MasciI. CipolloneG. PalaginiL. Insomnia and depressive symptoms during the menopausal transition: Theoretical and therapeutic implications of a self-reinforcing feedback loop.Maturitas2019123788110.1016/j.maturitas.2019.02.00731027682
     [Google Scholar]
  10. ChlebowskiR.T. AndersonG.L. GassM. LaneD.S. AragakiA.K. KullerL.H. MansonJ.E. StefanickM.L. OckeneJ. SartoG.E. JohnsonK.C. Wactawski-WendeJ. RavdinP.M. SchenkenR. HendrixS.L. RajkovicA. RohanT.E. YasmeenS. PrenticeR.L.WHI investigators Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women.JAMA2010304151684169210.1001/jama.2010.150020959578
     [Google Scholar]
  11. ChristJ.P. GunningM.N. PallaG. EijkemansM.J.C. LambalkC.B. LavenJ.S.E. FauserB.C.J.M. Estrogen deprivation and cardiovascular disease risk in primary ovarian insufficiency.Fertil. Steril.20181094594600.e110.1016/j.fertnstert.2017.11.03529605405
     [Google Scholar]
  12. ClarkeB.L. KhoslaS. Physiology of bone loss.Radiol. Clin. North Am.201048348349510.1016/j.rcl.2010.02.01420609887
     [Google Scholar]
  13. ClemettD. SpencerC.M. Raloxifene: A review of its use in postmenopausal osteoporosis.Drugs200060237941110.2165/00003495‑200060020‑0001310983739
     [Google Scholar]
  14. CobinR.H. GoodmanN.F. American association of clinical endocrinologists and American college of endocrinology position statement on menopause-2017 update.Endocr. Pract.201723786988110.4158/EP171828.PS28703650
     [Google Scholar]
  15. CoelinghBennink H.J. Estetrol review: Profile and potential clinical applications.Climacteric200811Suppl. 14758
     [Google Scholar]
  16. CollinsP. WebbC.M. de VilliersT.J. StevensonJ.C. PanayN. BaberR.J. Cardiovascular risk assessment in women – An update.Climacteric201619432933610.1080/13697137.2016.119857427327421
     [Google Scholar]
  17. Cordina-DuvergerE. TruongT. AngerA. SanchezM. ArveuxP. KerbratP. GuénelP. Risk of breast cancer by type of menopausal hormone therapy: A case-control study among post-menopausal women in France.PLoS One2013811e7801610.1371/journal.pone.007801624223752
     [Google Scholar]
  18. de VilliersT.J. HallJ.E. PinkertonJ.V. Cerdas PérezS. ReesM. YangC. PierrozD.D. Revised global consensus statement on menopausal hormone therapy.Climacteric201619431331510.1080/13697137.2016.119604727322027
     [Google Scholar]
  19. de VilliersT.J. PinesA. PanayN. GambaccianiM. ArcherD.F. BaberR.J. DavisS.R. GompelA.A. HendersonV.W. LangerR. LoboR.A. Plu-BureauG. SturdeeD.W. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health.Climacteric201316331633710.3109/13697137.2013.79568323672656
     [Google Scholar]
  20. DoranP.M KhoslaS. Postmenopausal Osteoporosis.Osteoporosis:Genetics, Prevention and TreatmentSpringerUS: Boston, MA,1999313515410.1007/978‑1‑4615‑5115‑7_9
     [Google Scholar]
  21. FormosoG. PerroneE. MaltoniS. BalduzziS. WilkinsonJ. BaseviV. MarataA.M. MagriniN. D’AmicoR. BassiC. MaestriE. Short-term and long-term effects of tibolone in postmenopausal women.Cochrane Libr.2016201611CD00853610.1002/14651858.CD008536.pub327733017
     [Google Scholar]
  22. FritzH. SeelyD. FlowerG. SkidmoreB. FernandesR. VadeboncoeurS. KennedyD. CooleyK. WongR. SagarS. SabriE. FergussonD. Soy, red clover, and isoflavones and breast cancer: A systematic review.PLoS One2013811e8196810.1371/journal.pone.008196824312387
     [Google Scholar]
  23. GambaccianiM. BigliaN. CagnacciA. CarusoS. CicinelliE. DE LeoV. DI CarloC. FarrisM. GamberaA. GuaschinoS. LanzoneA. PaolettiA. M. RussoN. VicariottoF. VillaP. VolpeA. Menopause and hormone replacement therapy: The 2017 Recommendations of the Italian Menopause Society.Minerva Ginecol.2018701273428975776
     [Google Scholar]
  24. GambaccianiM. LevanciniM. Hormone replacement therapy and the prevention of postmenopausal osteoporosis.Prz. Menopauzalny2014134213220
     [Google Scholar]
  25. GoldE.B. LeungK. CrawfordS.L. HuangM.H. WaetjenL.E. GreendaleG.A. Phytoestrogen and fiber intakes in relation to incident vasomotor symptoms.Menopause201320330531410.1097/gme.0b013e31826d2f4323435028
     [Google Scholar]
  26. GossetA. PouillèsJ.M. TrémollieresF. Menopausal hormone therapy for the management of osteoporosis.Best Pract. Res. Clin. Endocrinol. Metab.202135610155110.1016/j.beem.2021.10155134119418
     [Google Scholar]
  27. GraciaC.R. FreemanE.W. Onset of the menopause transition: The earliest signs and symptoms.Obstet. Gynecol. Clin. North Am.201845458559710.1016/j.ogc.2018.07.00230401544
     [Google Scholar]
  28. GrodsteinF. MansonJ.E. ColditzG.A. WillettW.C. SpeizerF.E. StampferM.J. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease.Ann. Intern. Med.20001331293394110.7326/0003‑4819‑133‑12‑200012190‑0000811119394
     [Google Scholar]
  29. GupteA.A. PownallH.J. HamiltonD.J. Estrogen: An emerging regulator of insulin action and mitochondrial function.J. Diabetes Res.201520151910.1155/2015/91658525883987
     [Google Scholar]
  30. HallJ. Neuroendocrine changes with reproductive aging in women.Semin. Reprod. Med.200725534435110.1055/s‑2007‑98474017710730
     [Google Scholar]
  31. HarmanS.M. VittinghoffE. BrintonE.A. BudoffM.J. CedarsM.I. LoboR.A. MerriamG.R. MillerV.M. NaftolinF. PalL. SantoroN. TaylorH.S. BlackD.M. Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes.Am. J. Med.2011124319920510.1016/j.amjmed.2010.09.02121396500
     [Google Scholar]
  32. HellströmA.C. MuntzingJ. The pollen extract Femal-a nonestrogenic alternative to hormone therapy in women with menopausal symptoms.Menopause201219782582910.1097/gme.0b013e31824017bc22334059
     [Google Scholar]
  33. JoffeH. GuthrieK.A. LaCroixA.Z. ReedS.D. EnsrudK.E. MansonJ.A.E. NewtonK.M. FreemanE.W. AndersonG.L. LarsonJ.C. HuntJ. ShifrenJ. RexrodeK.M. CaanB. SternfeldB. CarpenterJ.S. CohenL. Low-dose estrogen and the serotonin-norepinephrin reuptake inhibitor venlafaxine for vasomotor symptoms.JAMA Intern. Med.201417471058106610.1001/jamainternmed.2014.189124861828
     [Google Scholar]
  34. JohnsonA RobertsL ElkinsG Complementary and alternative medicine for menopause.J Evid Based Integr Med2019242515690X19829380
     [Google Scholar]
  35. KatonJ. ZephyrinL. MeoliA. HulugalleA. BoschJ. CallegariL. GalvanI. GrayK. HaegerK. HoffmireC. LevisS. MaE. MccabeJ. NillniY. PinelesS. ReddyS. SavitzD. ShawJ. PattonE. Reproductive health of women veterans: A systematic review of the literature from 2008 to 2017.Semin. Reprod. Med.201836631532210.1055/s‑0039‑167875031003246
     [Google Scholar]
  36. KenemansP. BundredN.J. FoidartJ.M. KubistaE. von SchoultzB. SismondiP. Vassilopoulou-SellinR. YipC.H. EgbertsJ. Mol-ArtsM. MulderR. van OsS. BeckmannM.W. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: A double-blind, randomised, non-inferiority trial.Lancet Oncol.200910213514610.1016/S1470‑2045(08)70341‑319167925
     [Google Scholar]
  37. KenemansP. SperoffL. Tibolone: Clinical recommendations and practical guidelines.Maturitas2005511212810.1016/j.maturitas.2005.02.01115883105
     [Google Scholar]
  38. KeramarisN.C. ChristodoulakosG.E. LambrinoudakiI.V. DalamangaA. AlexandrouA.P. BramisJ. BastounisE. CreatsasG.C. The differential effect of estrogen, estrogen–progestin and tibolone on coagulation inhibitors in postmenopausal women.Climacteric200710540040710.1080/1369713070162477317852143
     [Google Scholar]
  39. LambrinoudakiI. Progestogens in postmenopausal hormone therapy and the risk of breast cancer.Maturitas201477431131710.1016/j.maturitas.2014.01.00124485796
     [Google Scholar]
  40. LethabyA. MarjoribanksJ. KronenbergF. RobertsH. EdenJ. BrownJ. Phytoestrogens for menopausal vasomotor symptoms.Cochrane Database Syst. Rev.2013201312CD00139510.1002/14651858.CD001395.pub424323914
     [Google Scholar]
  41. LoboR.A. Hormone-replacement therapy: Current thinking.Nat. Rev. Endocrinol.201713422023110.1038/nrendo.2016.16427716751
     [Google Scholar]
  42. LoboR.A. Where are we 10 years after the women’s health initiative?J. Clin. Endocrinol. Metab.20139851771178010.1210/jc.2012‑407023493433
     [Google Scholar]
  43. LumsdenM.A. DaviesM. SarriG. Diagnosis and management of menopause: The national institute of health and care excellence (NICE) guideline.JAMA Intern. Med.201617681205120610.1001/jamainternmed.2016.276127322881
     [Google Scholar]
  44. LundbergG. WuP. WengerN. Menopausal hormone therapy: A comprehensive review.Curr. Atheroscler. Rep.20202283310.1007/s11883‑020‑00854‑832556827
     [Google Scholar]
  45. LunenfeldB. StrattonP. The clinical consequences of an ageing world and preventive strategies.Best Pract. Res. Clin. Obstet. Gynaecol.201327564365910.1016/j.bpobgyn.2013.02.00523541823
     [Google Scholar]
  46. LyytinenH. PukkalaE. YlikorkalaO. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy.Obstet. Gynecol.20091131657310.1097/AOG.0b013e31818e8cd619104361
     [Google Scholar]
  47. MansonJ.E. HsiaJ. JohnsonK.C. RossouwJ.E. AssafA.R. LasserN.L. TrevisanM. BlackH.R. HeckbertS.R. DetranoR. StricklandO.L. WongN.D. CrouseJ.R. SteinE. CushmanM. Estrogen plus progestin and the risk of coronary heart disease.N. Engl. J. Med.2003349652353410.1056/NEJMoa03080812904517
     [Google Scholar]
  48. MendozaN. De TeresaC. CanoA. GodoyD. Hita-ContrerasF. LapotkaM. LlanezaP. ManonellesP. Martínez-AmatA. OcónO. Rodríguez-AlcaláL. VélezM. Sánchez-BorregoR. Benefits of physical exercise in postmenopausal women.Maturitas201693838810.1016/j.maturitas.2016.04.01727137981
     [Google Scholar]
  49. The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society.Menopause201724772875310.1097/GME.000000000000092128650869
     [Google Scholar]
  50. NikiforovY.E. GneppD.R. Pathomorphology of thyroid gland lesions associated with radiation exposure: The Chernobyl experience and review of the literature.Adv. Anat. Pathol.199962789110.1097/00125480‑199903000‑0000210331070
     [Google Scholar]
  51. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society.Menopause201522111155117410.1097/GME.000000000000054626382310
     [Google Scholar]
  52. O’NeillS. EdenJ. The pathophysiology of menopausal symptoms.Obstetrics, Gynaecol. Reprod. Med.2017271030331010.1016/j.ogrm.2017.07.002
     [Google Scholar]
  53. PalaciosS. MejíaA. Progestogen safety and tolerance in hormonal replacement therapy.Expert Opin. Drug Saf.201615111515152510.1080/14740338.2016.122304127548404
     [Google Scholar]
  54. PalaciosS. Mejía RíosA. Bazedoxifene/conjugated estrogens combination for the treatment of the vasomotor symptoms associated with menopause and for prevention of osteoporosis in postmenopausal women.Drugs Today201551210711610.1358/dot.2015.51.2.228102325756066
     [Google Scholar]
  55. PandyaK.J. MorrowG.R. RoscoeJ.A. ZhaoH. HickokJ.T. PajonE. SweeneyT.J. BanerjeeT.K. FlynnP.J. Gabapentin for hot flashes in 420 women with breast cancer: A randomised double-blind placebo-controlled trial.Lancet2005366948881882410.1016/S0140‑6736(05)67215‑716139656
     [Google Scholar]
  56. PinkertonJ.V. Hormone therapy for postmenopausal women.N. Engl. J. Med.2020382544645510.1056/NEJMcp171478731995690
     [Google Scholar]
  57. Polo-KantolaP. RantalaM.J. Menopause, a curse or an opportunity? An evolutionary biological view.Acta Obstet. Gynecol. Scand.201998668768810.1111/aogs.1362831087567
     [Google Scholar]
  58. PowellS.L. GödeckeT. NikolicD. ChenS.N. AhnS. DietzB. FarnsworthN.R. van BreemenR.B. LankinD.C. PauliG.F. BoltonJ.L. In vitro serotonergic activity of black cohosh and identification of N(omega)-methylserotonin as a potential active constituent.J. Agric. Food Chem.20085624117181172610.1021/jf803298z19049296
     [Google Scholar]
  59. PriorJ.C. Ovarian aging and the perimenopausal transition: The paradox of endogenous ovarian hyperstimulation.Endocr. J.200526329730010.1385/ENDO:26:3:29716034185
     [Google Scholar]
  60. RarickL. United States regulatory considerations for intrauterine progestins for hormone replacement therapy.Contraception2007756Suppl.S140S14310.1016/j.contraception.2006.12.01117531606
     [Google Scholar]
  61. ReedM.J. KloosterboerH.J. Tibolone: A selective tissue estrogenic activity regulator (STEAR).Maturitas200448Suppl. 14610.1016/j.maturitas.2004.02.01315337241
     [Google Scholar]
  62. RossouwJ.E. AndersonG.L. PrenticeR.L. LaCroixA.Z. KooperbergC. StefanickM.L. JacksonR.D. BeresfordS.A. HowardB.V. JohnsonK.C. KotchenJ.M. OckeneJ. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women’s health initiative randomized controlled trial.JAMA2002288332133310.1001/jama.288.3.32112117397
     [Google Scholar]
  63. SchwersJ. ErikssonG. WiqvistN. DiczfalusyE. 15α-hydroxylation: A new pathway of estrogen metabolism in the human fetus and newborn.Biochim. Biophys. Acta, Gen. Subj.1965100131331610.1016/0304‑4165(65)90464‑214323645
     [Google Scholar]
  64. ShufeltC. MansonJ. Managing menopause by combining evidence with clinical judgment.Clin. Obstet. Gynecol.201861347047910.1097/GRF.000000000000037829762147
     [Google Scholar]
  65. SiminoskiK. JiangG. AdachiJ.D. HanleyD.A. ClineG. IoannidisG. HodsmanA. JosseR.G. KendlerD. OlszynskiW.P. Ste MarieL.G. EastellR. Accuracy of height loss during prospective monitoring for detection of incident vertebral fractures.Osteoporos. Int.200516440341010.1007/s00198‑004‑1709‑z15309381
     [Google Scholar]
  66. SoaresC.N. Depression and menopause: An update on current knowledge and clinical management for this critical window.Med. Clin. North Am.2019103465166710.1016/j.mcna.2019.03.00131078198
     [Google Scholar]
  67. StanczykF.Z. HapgoodJ.P. WinerS. MishellD.R.Jr Progestogens used in postmenopausal hormone therapy: Differences in their pharmacological properties, intracellular actions, and clinical effects.Endocr. Rev.201334217120810.1210/er.2012‑100823238854
     [Google Scholar]
  68. StuenkelC.A. DavisS.R. GompelA. LumsdenM.A. MuradM.H. PinkertonJ.V. SantenR.J. Treatment of symptoms of the menopause: An Endocrine Society clinical practice guideline.J. Clin. Endocrinol. Metab.2015100113975401110.1210/jc.2015‑223626444994
     [Google Scholar]
  69. StuteP. NeulenJ. WildtL. The impact of micronized progesterone on the endometrium: A systematic review.Climacteric201619431632810.1080/13697137.2016.118712327277331
     [Google Scholar]
  70. TaylorH.S. MansonJ.E. Update in hormone therapy use in menopause.J. Clin. Endocrinol. Metab.201196225526410.1210/jc.2010‑053621296989
     [Google Scholar]
  71. TrimbleM. ReynoldsE. MartinR. BurneoJ. PrasadA. KotagalP. CostaM. WyllieE. WolgamuthB. StoneJ. CarsonA. Psychogenic nonepileptic seizures in women.Semin. Neurol.2017376624631
     [Google Scholar]
  72. TrolleC. HjerrildB. CleemannL. MortensenK.H. GravholtC.H. Sex hormone replacement in Turner syndrome.Endocrine201241220021910.1007/s12020‑011‑9569‑822147393
     [Google Scholar]
  73. ValdesA. BajajT. Estrogen therapy.Treasure Island, FLStatPearls2021
     [Google Scholar]
  74. VarytėG. BartkevičienėD. Pelvic radiation therapy induced vaginal stenosis: A review of current modalities and recent treatment advances.Medicina202157433610.3390/medicina5704033633915994
     [Google Scholar]
  75. VishwakarmaG. NdetanH. DasD.N. GuptaG. SuryavanshiM. MehtaA. SinghK.P. Reproductive factors and breast cancer risk: A meta-analysis of case–control studies in Indian women.South Asian J. Cancer20198208008410.4103/sajc.sajc_317_18 31069183
     [Google Scholar]
  76. VisserM. Coellingh BenninkH.J.T. Clinical application for estetrol.J. Steroid Biochem. Mol. Biol.2009114858910.1016/j.jsbmb.2008.12.01319167495
     [Google Scholar]
  77. YenenM.C. DedeM. GoktolgaU. KuçukT. PabuçcuR. Hormone replacement therapy in postmenopausal women with benign fibrocystic mastopathy.Climacteric20036214615010.1080/cmt.6.2.146.15012841885
     [Google Scholar]
  78. SinghS. BestC. DunnS. LeylandN. WolfmanW.L. No. 292-abnormal uterine bleeding in pre-menopausal women.J. Obstet. Gynaecol. Can.2018405e391e41510.1016/j.jogc.2018.03.00729731212
     [Google Scholar]
  79. Hussain MallhiT. Habib KhanY. Hayat KhanA. MahmoodQ. Haroon KhalidS. SaleemM. Managing hot flushes in menopausal women: A review.J. Coll. Physicians Surg. Pak.201828646046510.29271/jcpsp.2018.06.46029848424
     [Google Scholar]
  80. KaufertP.A. Myth and the menopause.Sociol. Health Illn.19824214116610.1111/1467‑9566.ep11339905
     [Google Scholar]
  81. NedrowA. MillerJ. WalkerM. NygrenP. HuffmanL.H. NelsonH.D. Complementary and alternative therapies for the management of menopause-related symptoms: A systematic evidence review.Arch. Intern. Med.2006166141453146510.1001/archinte.166.14.145316864755
     [Google Scholar]
  82. TiwariP. KadiriS.K. DubeyP. SinghD. KhobragadeD.S. SahuP.K. Understanding fertile window: A key to pregnancy as well as contraception.Curr. Womens Health Rev.2025212e11012422554010.2174/0115734048282403240101112918
     [Google Scholar]
  83. FaubionS.S. CrandallC.J. DavisL. El KhoudaryS.R. HodisH.N. LoboR.A. MakiP.M. MansonJ.E. PinkertonJ.V. SantoroN.F. ShifrenJ.L. The 2022 hormone therapy position statement of the North American menopause society.Menopause202229776779410.1097/GME.000000000000202835797481
     [Google Scholar]
  84. GoldB.T. KimC. JohnsonN.F. KryscioR.J. SmithC.D. Lifelong bilingualism maintains neural efficiency for cognitive control in aging.J. Neurosci.201333238739610.1523/JNEUROSCI.3837‑12.201323303919
     [Google Scholar]
  85. FritzH. AbdelsalamM. AliK.A. BingenB. CollinsA.S. FowlerA.R. GhebreabW. HauzenbergerC.A. JohnsonP.R. KuskyT.M. MaceyP. MuhongoS. SternR.J. ViolaG. Orogen styles in the East African Orogen: A review of the neoproterozoic to cambrian tectonic evolution.J. Afr. Earth Sci.2013866510610.1016/j.jafrearsci.2013.06.00427065752
     [Google Scholar]
/content/journals/cwhr/10.2174/0115734048352354250406163635
Loading
Comprehensive Guide to Menopausal Therapy: Options and Outcomes
Curr Womens Health Rev. 22, E15734048352354 (2026); https://doi.org/10.2174/0115734048352354250406163635
/content/journals/cwhr/10.2174/0115734048352354250406163635
/content/journals/cwhr/10.2174/0115734048352354250406163635
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Follicle-stimulating hormone; menopausal hormone therapy; premenstrual syndrome; selective serotonin reuptake inhibitors; vaginal mucosa; women's health initiative

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test